“The current scenario has reached an oversold condition at key support levels and we recommend taking long positions. The broader market, which was overheated, has seen a healthy decline and it appears that the price correction phase is over and will likely lead to a bottoming and a resumption of the bull phase,” it added.
Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY
Laurus Labs shares rose 3.79% to Rs 2,329 after the pharmaceutical company reported strong Q2FY27 results. Revenue increased 33% year-on-year to Rs 2,206 crore, while
October 30, 2026